Comparison of Parametric Survival Extrapolation Approaches Incorporating General Population Mortality for Adequate Health Technology Assessment of New Oncology Drugs.

OBJECTIVES Survival extrapolation of trial outcomes is required for health economic evaluation. Generally, all-cause mortality (ACM) is modeled using standard parametric distributions, often without distinguishing disease-specific/excess mortality and general population background mortality (GPM). Recent National Institute for Health and Care Excellence guidance (Technical Support Document 21) recommends adding GPM hazards to disease-specific/excess mortality hazards in the log-likelihood function ("internal additive hazards"). This article compares alternative extrapolation approaches with and without GPM adjustment. METHODS Survival extrapolations using the internal additive hazards approach (1) are compared to no GPM adjustment (2), applying GPM hazards once ACM hazards drop below GPM hazards (3), adding GPM hazards to ACM hazards (4), and proportional hazards for ACM versus GPM hazards (5). The fit, face validity, mean predicted life-years, and corresponding uncertainty measures are assessed for the active versus control arms of immature and mature (30- and 75-month follow-up) multiple myeloma data and mature (64-month follow-up) breast cancer data. RESULTS The 5 approaches yielded considerably different outcomes. Incremental mean predicted life-years vary most in the immature multiple myeloma data set. The lognormal distribution (best statistical fit for approaches 1-4) produces survival increments of 3.5 (95% credible interval: 1.4-5.3), 8.5 (3.1-13.0), 3.5 (1.3-5.4), 2.9 (1.1-4.5), and 1.6 (0.4-2.8) years for approaches 1 to 5, respectively. Approach 1 had the highest face validity for all data sets. Uncertainty over parametric distributions was comparable for GPM-adjusted approaches 1, 3, and 4, and much larger for approach 2. CONCLUSION This study highlights the importance of GPM adjustment, and particularly of incorporating GPM hazards in the log-likelihood function of standard parametric distributions.

[1]  Nicky J Welton,et al.  NICE DSU Technical Support Document 18 , 2011 .

[2]  Jiqiang Guo,et al.  Stan: A Probabilistic Programming Language. , 2017, Journal of statistical software.

[3]  D Elbourne,et al.  Randomised controlled trial and parallel economic evaluation of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR). , 2010, Health technology assessment.

[5]  A. Linde.  DIC in variable selection , 2005 .

[6]  Aki Vehtari,et al.  Practical Bayesian model evaluation using leave-one-out cross-validation and WAIC , 2015, Statistics and Computing.

[7]  M. Pitt,et al.  The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche. , 2010, Health technology assessment.

[8]  M. Plummer.  Penalized loss functions for Bayesian model comparison. , 2008, Biostatistics.

[9]  Gianluca Baio,et al.  survHE: Survival Analysis for Health Economic Evaluation and Cost-Effectiveness Modeling , 2020, J. Stat. Softw..

[10]  S. Twu,et al.  Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy. , 2006, QJM : monthly journal of the Association of Physicians.

[11]  C. Magnani,et al.  Life expectancy as an indicator of outcome in follow-up of population-based cancer registries: the example of childhood leukemia. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  M. Weinstein,et al.  Cost‐effectiveness analysis of oxaliplatin compared with 5‐fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US , 2007, Cancer.

[13]  Andrea Manca,et al.  Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods , 2016, Medical decision making : an international journal of the Society for Medical Decision Making.

[14]  Sung-Bae Kim,et al.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.

[15]  M Westwood,et al.  Colour vision testing for diabetic retinopathy: a systematic review of diagnostic accuracy and economic evaluation. , 2009, Health technology assessment.

[16]  S. Ward,et al.  Hormonal therapies for early breast cancer: systematic review and economic evaluation. , 2007, Health technology assessment.

[17]  Z. Philips,et al.  Network meta‐analysis of parametric survival curves , 2010, Research synthesis methods.

[18]  D. Chambers,et al.  Sugammadex for the reversal of muscle relaxation in general anaesthesia: a systematic review and economic assessment. , 2010, Health technology assessment.

[19]  M. Postma,et al.  Extrapolating Survival Data Using Historical Trial-Based a Priori Distributions. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[20]  D. Esseltine,et al.  Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P Barton,et al.  The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. , 2004, Health technology assessment.

[22]  Nicholas R Latimer,et al.  Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[23]  Jing-Shiang Hwang,et al.  Estimation of life expectancy and the expected years of life lost in patients with major cancers: extrapolation of survival curves under high-censored rates. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[24]  Sumio Watanabe,et al.  Asymptotic Equivalence of Bayes Cross Validation and Widely Applicable Information Criterion in Singular Learning Theory , 2010, J. Mach. Learn. Res..

[25]  H. Doll,et al.  A systematic review of outcome measures used in forensic mental health research with consensus panel opinion. , 2010, Health technology assessment.

[26]  L. Seeff,et al.  The impact of detection and treatment on lifetime medical costs for patients with precancerous polyps and colorectal cancer. , 2009, Health economics.

[27]  J. Cerhan,et al.  Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies , 2018, Blood Cancer Journal.

[28]  Bin Jiang,et al.  Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. , 2008, The New England journal of medicine.

[29]  P Barton,et al.  A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. , 2006, Health technology assessment.

[30]  J. Hwang,et al.  Monte Carlo estimation of extrapolation of quality-adjusted survival for follow-up studies. , 1999, Statistics in medicine.

[31]  Mats Lambe,et al.  Estimating the loss in expectation of life due to cancer using flexible parametric survival models , 2013, Statistics in medicine.

[32]  M. Sculpher,et al.  The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease - a UK collaborative study. The REFLUX trial. , 2008, Health technology assessment.

[33]  Paul-Christian Bürkner,et al.  brms: An R Package for Bayesian Multilevel Models Using Stan , 2017 .

[34]  Nicky J Welton,et al.  Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves , 2012, BMC Medical Research Methodology.

[35]  Felicitie C. Bell,et al.  Life Tables for the United States Social Security Area 1900-2100 , 2002 .